Avdeev, 46 patient N-acetylcysteine late treatment study: 69% lower mortality [p=0.34], 77% lower ventilation [p=0.18], 77% lower ICU admission [p=0.18], and 15% shorter hospitalization [p=0.01] https://c19p.org/avdeev
copied to clipboard
N-acetylcysteine for the treatment of COVID-19 among hospitalized patients
et al., Journal of Infection, doi:10.1016/j.jinf.2021.07.003
Prospective study of 24 hospitalized COVID-19 patients in Russia treated with NAC, and 22 matched controls, showing significantly improved SpO2/FiO2, and significantly shorter hospitalization with treatment.
|
risk of death, 69.4% lower, RR 0.31, p = 0.34, treatment 1 of 24 (4.2%), control 3 of 22 (13.6%), NNT 11.
|
|
risk of mechanical ventilation, 77.1% lower, RR 0.23, p = 0.18, treatment 1 of 24 (4.2%), control 4 of 22 (18.2%), NNT 7.1.
|
|
risk of ICU admission, 77.1% lower, RR 0.23, p = 0.18, treatment 1 of 24 (4.2%), control 4 of 22 (18.2%), NNT 7.1.
|
|
hospitalization time, 15.4% lower, relative time 0.85, p = 0.01, treatment 24, control 22.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Avdeev et al., 7/9/2021, retrospective, Russia, Europe, peer-reviewed, 4 authors, study period 12 April, 2020 - 20 June, 2020, average treatment delay 7.2 days.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.